Suraksha Q2 profit rises 69% as EBITDA margin reaches 36.7%
Key highlights
- Suraksha reported Q2 FY27 PAT of Rs 14.95 crore, up 69% year on year.
- Q2 FY27 EBITDA margin rose to 36.7% from 31.7% in Q2 FY26.
- Centres less than two years old improved to an 11.8% EBITDA margin from negative 16.8%.
- Suraksha ended Q2 FY27 with 77 centres after adding five during the quarter.
powered by IRIS

Suraksha Diagnostic Limited reported a 69% year-on-year rise in Q2 FY27 profit after tax to Rs 14.95 crore, while total income increased 26.4% to Rs 100.57 crore and EBITDA margin expanded to 36.7% from 31.7%. The September-quarter result also included Rs 861 of EBITDA per patient and five new centres.
Know Suraksha Diagnostic inside out
Results, valuation, peers and who's buying, in one view.
How did Suraksha’s Q2 FY27 earnings change?
Suraksha’s Q2 FY27 profit after tax, or PAT, increased to Rs 14.95 crore from Rs 8.828 crore in Q2 FY26, a 69% year-on-year increase. Total income grew more slowly, by 26.4%, to Rs 100.57 crore from Rs 79.58 crore, meaning profit growth exceeded revenue growth during the quarter ended September 30, 2026.
Earnings before interest, tax, depreciation and amortisation, or EBITDA, rose to Rs 36.32 crore from Rs 24.97 crore. That increase lifted the EBITDA margin by 500 basis points, or 5 percentage points, to 36.7% from 31.7%. PAT margin was 15.1% in Q2 FY27, based on the company’s reported Rs 14.95 crore of PAT.
The difference between 45.5% EBITDA growth and 26.4% income growth coincided with the margin expansion. Management described Q2 and the first half as periods of improved operating profitability, while stating it remained focused on throughput, operating leverage and profitability as newer centres mature.
What did Suraksha report on patient and test activity?
Suraksha served 4.2 lakh patients and performed 24 lakh tests in Q2 FY27, equating to 5.7 tests per patient. Revenue per patient was Rs 2,348 and EBITDA per patient was Rs 861, giving a per-patient measure alongside the reported 36.7% overall EBITDA margin.
Management later clarified during the call that the number of tests had increased 9%, rather than about 5%, after an error in the originally stated test number was corrected. It did not provide a numerical split of higher revenue per test among advanced radiology, genomics or other categories, but said rising revenue per test indicated that higher-end tests were growing in number.
For H1 FY27, Suraksha served 8 lakh patients and performed 45 lakh tests, or 5.63 tests per patient. Revenue per patient was Rs 2,335 and EBITDA per patient was Rs 849. The Q2 figures were therefore Rs 13 higher for revenue per patient and Rs 12 higher for EBITDA per patient than the first-half averages, although the two periods are not directly comparable because Q2 is included in H1.
How did Suraksha’s first-half performance compare with last year?
Suraksha’s H1 FY27 total income rose 23.7% to Rs 189.31 crore from Rs 153.07 crore in H1 FY26, while PAT increased 54% to Rs 27.796 crore from Rs 18 crore. H1 EBITDA reached Rs 67.85 crore, compared with Rs 49.62 crore a year earlier, and the EBITDA margin was 36.3%.
The first-half margin was 40 basis points below Q2’s 36.7%, while Q2 PAT margin of 15.1% was 20 basis points above the H1 PAT margin of 14.9%. These reported differences show that the September quarter carried a slightly higher operating and net margin than the six-month average.
The company ended the period with 77 centres after adding five during the quarter. Management said the additions included Suraksha’s entry into Jharkhand, while infrastructure and equipment installation for Tripura were under way and operations there were expected to begin in the second half of FY27.
Got a follow-up? Ask IRIS
Are newer Suraksha centres becoming more profitable?
Suraksha said mature centres generated a 42% EBITDA margin in Q2 FY27, while centres less than two years old recorded an 11.8% margin, improving from a negative 16.8% in the corresponding prior-year quarter. The 28.6-percentage-point swing for the newer-centre group was presented as evidence of improving throughput and capacity utilisation.
Management said the 11.8% figure is a blended result that includes pre-operative expenses and centres that may be less than one quarter old. It added that centres more than one year old had margins of about 30%, whereas the mature-centre category was at 42% in Q2 FY27. This separates the earnings profile of established sites from the costs of recently launched locations.
The company’s operating model uses hubs with magnetic resonance imaging, or MRI, and computed tomography, or CT, scanners and spoke centres that book cases for these services. Management said this hub-and-spoke arrangement is intended to increase utilisation of imaging assets, while clusters, network density, existing infrastructure and centralised procurement support expansion.
What has Suraksha said about margins, expansion and seasonality?
Suraksha management said it does not expect EBITDA margin to come under pressure from expansion because maturing centres should balance the effect of newly opened sites. It gave a steady-state EBITDA margin expectation of about 34% to 35% for the following year, while also saying the 42% mature-centre margin was the highest margin it expected to discuss at present.
On network scale, management said it wished to reach 100 centres by the end of FY28, followed by a slower pace of perhaps five to 10 centres. It also said the share of revenue from the rest of Bengal, which was about 29% in H1 FY27, should rise as the company expands more heavily there and enters or develops Jharkhand, Assam and Bihar. Greater Kolkata accounted for 67% of H1 FY27 revenue.
Management also warned that Q3 revenue would decline from the Rs 100 crore quarterly level because of industry seasonality during the festival period, and said Q4 is usually better than Q3. When asked whether a minimum Rs 100 crore run rate could be maintained from Q4 into the next financial year, management answered yes.
Conclusion
Suraksha’s Q2 FY27 figures show that profit increased faster than income, with PAT up 69% to Rs 14.95 crore against 26.4% total-income growth and a 500-basis-point expansion in EBITDA margin to 36.7%. The company also reported Rs 861 of EBITDA per patient, while the margin of centres under two years old moved to 11.8% from negative 16.8% a year earlier.
The next disclosed milestones are the expected second-half FY27 start of Tripura operations, continued ramp-up of the five centres added in Q2, and management’s plan to reach 100 centres by the end of FY28. Management has also flagged a seasonal Q3 revenue decline before the typically better Q4, making the progression of throughput and newer-centre profitability the key reported operating matters to watch.


